B7-h4 is highly expressed in ductal and lobular breast cancer - PubMed (original) (raw)
Comparative Study
B7-h4 is highly expressed in ductal and lobular breast cancer
Barbara Tringler et al. Clin Cancer Res. 2005.
Abstract
Purpose: This study was designed to investigate the expression of B7-H4 protein, a member of the B7 family that is involved in the regulation of antigen-specific immune responses, in normal breast and in primary and metastatic breast carcinomas.
Experimental design: Archival formalin-fixed tissue blocks from breast cancers and normal somatic tissues were evaluated for B7-H4 expression by immunohistochemistry with manual and automated image analysis. The proportion of B7-H4-positive cells and the intensity of B7-H4 staining were compared with histologic type, grade, stage, hormone receptor status, and HER-2/neu status.
Results: B7-H4 was detected in 165 of 173 (95.4%) primary breast cancers and in 240 of 246 (97.6%) metastatic breast cancers. B7-H4 staining intensity was greater in invasive ductal carcinomas [24.61 relative units (RU)] and in invasive lobular carcinomas (15.23 RU) than in normal breast epithelium (4.30 RU, P = 0.0003). Increased staining intensity was associated with negative progesterone receptor status (P = 0.014) and history of neoadjuvant chemotherapy (P = 0.004), and the proportion of B7-H4-positive cells was associated with negative progesterone receptor (P = 0.001) and negative HER-2/neu (P = 0.024) status. However, there was no statistically significant relationship between the proportion of B7-H4-positive cells or staining intensity and grade, stage, or other clinicopathologic variables. Low levels of B7-H4 expression were also detected in epithelial cells of the female genital tract, lung, pancreas, and kidney, but B7-H4 was generally absent in most other normal somatic tissues.
Conclusions: The nearly ubiquitous expression of B7-H4 in breast cancer, independent of tumor grade or stage, suggests a critical role for this protein in breast cancer biology.
Similar articles
- B7-H4 overexpression in ovarian tumors.
Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR. Tringler B, et al. Gynecol Oncol. 2006 Jan;100(1):44-52. doi: 10.1016/j.ygyno.2005.08.060. Epub 2005 Oct 26. Gynecol Oncol. 2006. PMID: 16256178 - Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Ariga R, et al. Breast J. 2005 Jul-Aug;11(4):278-80. doi: 10.1111/j.1075-122x.2005.21463.x. Breast J. 2005. PMID: 15982396 - B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR. Miyatake T, et al. Gynecol Oncol. 2007 Jul;106(1):119-27. doi: 10.1016/j.ygyno.2007.03.039. Epub 2007 May 16. Gynecol Oncol. 2007. PMID: 17509674 - Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
Yoder BJ, Wilkinson EJ, Massoll NA. Yoder BJ, et al. Breast J. 2007 Mar-Apr;13(2):172-9. doi: 10.1111/j.1524-4741.2007.00393.x. Breast J. 2007. PMID: 17319859 Review. - Molecular evolutionary patterns in breast cancer.
Shackney SE, Silverman JF. Shackney SE, et al. Adv Anat Pathol. 2003 Sep;10(5):278-90. doi: 10.1097/00125480-200309000-00003. Adv Anat Pathol. 2003. PMID: 12973049 Review.
Cited by
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Yin N, et al. Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z. Signal Transduct Target Ther. 2024. PMID: 38773064 Free PMC article. Review. - A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Xu H, Lewis A, Mamidi S, Medvedev S, Kim H, Anderton J, Tang EJ, Ferman B, Coats S, Wilkinson RW, Brown E, Powell DJ Jr, Simpkins F. Gitto SB, et al. Clin Cancer Res. 2024 Apr 15;30(8):1567-1581. doi: 10.1158/1078-0432.CCR-23-1079. Clin Cancer Res. 2024. PMID: 37882675 Free PMC article. - The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.
Zhou L, Wu J, Ruan M, Xiao Y, Lan H, Wu Q, Yu CW, Zhang Q. Zhou L, et al. Breast Cancer Res. 2023 Oct 4;25(1):115. doi: 10.1186/s13058-023-01721-5. Breast Cancer Res. 2023. PMID: 37794509 Free PMC article. - The novel epithelial-mesenchymal transition-related proteins and their therapeutic targets in cholangiocarcinoma: a narrative review.
Kimawaha P, Techasen A. Kimawaha P, et al. J Gastrointest Oncol. 2023 Jun 30;14(3):1593-1612. doi: 10.21037/jgo-22-1126. Epub 2023 May 26. J Gastrointest Oncol. 2023. PMID: 37435208 Free PMC article. Review. - The immune checkpoint molecule, VTCN1/B7-H4, guides differentiation and suppresses proinflammatory responses and MHC class I expression in an embryonic stem cell-derived model of human trophoblast.
Zhou J, Tian Y, Qu Y, Williams M, Yuan Y, Karvas RM, Sheridan MA, Schulz LC, Ezashi T, Roberts MR, Schust DJ. Zhou J, et al. Front Endocrinol (Lausanne). 2023 Mar 16;14:1069395. doi: 10.3389/fendo.2023.1069395. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37008954 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous